vs
Apellis Pharmaceuticals, Inc.（APLS）与UNITIL CORP（UTL）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是UNITIL CORP的1.2倍（$199.9M vs $161.5M），UNITIL CORP净利率更高（11.8% vs -29.5%，领先41.3%），UNITIL CORP同比增速更快（26.7% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-36.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -4.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Unitil是一家跨州电力与天然气公用事业公司，业务覆盖美国新罕布什尔州、马萨诸塞州与缅因州。公司最早前身是1849年在缅因州成立的波特兰煤气灯公司，现企业主体于1984年设立，总部位于新罕布什尔州。目前公司总市值约6.8651亿美元，为约10.24万电力客户、超7.59万天然气客户提供服务。
APLS vs UTL — 直观对比
营收规模更大
APLS
是对方的1.2倍
$161.5M
营收增速更快
UTL
高出32.6%
-5.9%
净利率更高
UTL
高出41.3%
-29.5%
自由现金流更多
APLS
多$22.0M
$-36.3M
两年增速更快
APLS
近两年复合增速
-4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $161.5M |
| 净利润 | $-59.0M | $19.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 21.5% |
| 净利率 | -29.5% | 11.8% |
| 营收同比 | -5.9% | 26.7% |
| 净利润同比 | -62.2% | 21.8% |
| 每股收益（稀释后） | $-0.40 | $1.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSUTL
| Q4 25 | $199.9M | $161.5M | ||
| Q3 25 | $458.6M | $101.1M | ||
| Q2 25 | $178.5M | $102.6M | ||
| Q1 25 | $166.8M | $170.8M | ||
| Q4 24 | $212.5M | $127.5M | ||
| Q3 24 | $196.8M | $92.9M | ||
| Q2 24 | $199.7M | $95.7M | ||
| Q1 24 | $172.3M | $178.7M |
净利润APLSUTL
| Q4 25 | $-59.0M | $19.0M | ||
| Q3 25 | $215.7M | $-300.0K | ||
| Q2 25 | $-42.2M | $4.0M | ||
| Q1 25 | $-92.2M | $27.5M | ||
| Q4 24 | $-36.4M | $15.6M | ||
| Q3 24 | $-57.4M | $0 | ||
| Q2 24 | $-37.7M | $4.3M | ||
| Q1 24 | $-66.4M | $27.2M |
营业利润率APLSUTL
| Q4 25 | -25.6% | 21.5% | ||
| Q3 25 | 48.7% | 6.9% | ||
| Q2 25 | -18.6% | 13.0% | ||
| Q1 25 | -50.0% | 27.0% | ||
| Q4 24 | -12.3% | 22.1% | ||
| Q3 24 | -24.0% | 6.2% | ||
| Q2 24 | -14.7% | 13.0% | ||
| Q1 24 | -36.0% | 24.7% |
净利率APLSUTL
| Q4 25 | -29.5% | 11.8% | ||
| Q3 25 | 47.0% | -0.3% | ||
| Q2 25 | -23.6% | 3.9% | ||
| Q1 25 | -55.3% | 16.1% | ||
| Q4 24 | -17.1% | 12.2% | ||
| Q3 24 | -29.2% | — | ||
| Q2 24 | -18.9% | 4.5% | ||
| Q1 24 | -38.5% | 15.2% |
每股收益（稀释后）APLSUTL
| Q4 25 | $-0.40 | $1.05 | ||
| Q3 25 | $1.67 | $-0.02 | ||
| Q2 25 | $-0.33 | $0.25 | ||
| Q1 25 | $-0.74 | $1.69 | ||
| Q4 24 | $-0.30 | $0.97 | ||
| Q3 24 | $-0.46 | $0.00 | ||
| Q2 24 | $-0.30 | $0.27 | ||
| Q1 24 | $-0.54 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $15.6M |
| 总债务越低越好 | — | $670.5M |
| 股东权益账面价值 | $370.1M | $609.6M |
| 总资产 | $1.1B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资APLSUTL
| Q4 25 | $466.2M | $15.6M | ||
| Q3 25 | $479.2M | $14.6M | ||
| Q2 25 | $370.0M | $8.5M | ||
| Q1 25 | $358.4M | $10.2M | ||
| Q4 24 | $411.3M | $6.3M | ||
| Q3 24 | $396.9M | $6.3M | ||
| Q2 24 | $360.1M | $2.8M | ||
| Q1 24 | $325.9M | $6.3M |
总债务APLSUTL
| Q4 25 | — | $670.5M | ||
| Q3 25 | — | $670.5M | ||
| Q2 25 | — | $640.7M | ||
| Q1 25 | — | $642.1M | ||
| Q4 24 | — | $643.3M | ||
| Q3 24 | — | $643.3M | ||
| Q2 24 | — | $511.3M | ||
| Q1 24 | $93.1M | $512.8M |
股东权益APLSUTL
| Q4 25 | $370.1M | $609.6M | ||
| Q3 25 | $401.2M | $597.2M | ||
| Q2 25 | $156.3M | $532.8M | ||
| Q1 25 | $164.2M | $534.1M | ||
| Q4 24 | $228.5M | $512.5M | ||
| Q3 24 | $237.1M | $502.4M | ||
| Q2 24 | $264.3M | $508.8M | ||
| Q1 24 | $266.7M | $510.8M |
总资产APLSUTL
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $1.9B | ||
| Q2 25 | $821.4M | $1.9B | ||
| Q1 25 | $807.3M | $1.9B | ||
| Q4 24 | $885.1M | $1.8B | ||
| Q3 24 | $901.9M | $1.7B | ||
| Q2 24 | $904.5M | $1.7B | ||
| Q1 24 | $831.9M | $1.7B |
负债/权益比APLSUTL
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 1.20× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | 0.35× | 1.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $21.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-36.3M |
| 自由现金流率自由现金流/营收 | -7.1% | -22.5% |
| 资本支出强度资本支出/营收 | 0.1% | 35.7% |
| 现金转化率经营现金流/净利润 | — | 1.13× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-53.8M |
8季度趋势，按日历期对齐
经营现金流APLSUTL
| Q4 25 | $-14.2M | $21.4M | ||
| Q3 25 | $108.5M | $15.6M | ||
| Q2 25 | $4.4M | $42.2M | ||
| Q1 25 | $-53.4M | $52.1M | ||
| Q4 24 | $19.4M | $23.3M | ||
| Q3 24 | $34.1M | $26.1M | ||
| Q2 24 | $-8.3M | $49.9M | ||
| Q1 24 | $-133.0M | $26.6M |
自由现金流APLSUTL
| Q4 25 | $-14.3M | $-36.3M | ||
| Q3 25 | $108.3M | $-39.0M | ||
| Q2 25 | $4.4M | $2.0M | ||
| Q1 25 | $-53.4M | $19.5M | ||
| Q4 24 | $19.3M | $-32.3M | ||
| Q3 24 | — | $-31.3M | ||
| Q2 24 | $-8.4M | $13.2M | ||
| Q1 24 | $-133.3M | $6.4M |
自由现金流率APLSUTL
| Q4 25 | -7.1% | -22.5% | ||
| Q3 25 | 23.6% | -38.6% | ||
| Q2 25 | 2.5% | 1.9% | ||
| Q1 25 | -32.0% | 11.4% | ||
| Q4 24 | 9.1% | -25.3% | ||
| Q3 24 | — | -33.7% | ||
| Q2 24 | -4.2% | 13.8% | ||
| Q1 24 | -77.3% | 3.6% |
资本支出强度APLSUTL
| Q4 25 | 0.1% | 35.7% | ||
| Q3 25 | 0.0% | 54.0% | ||
| Q2 25 | 0.0% | 39.2% | ||
| Q1 25 | 0.0% | 19.1% | ||
| Q4 24 | 0.0% | 43.6% | ||
| Q3 24 | 0.0% | 61.8% | ||
| Q2 24 | 0.0% | 38.3% | ||
| Q1 24 | 0.2% | 11.3% |
现金转化率APLSUTL
| Q4 25 | — | 1.13× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 10.55× | ||
| Q1 25 | — | 1.89× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 11.60× | ||
| Q1 24 | — | 0.98× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
UTL
暂无分部数据
